{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=117&status=ACTIVE_NOT_RECRUITING", "query": { "status": "ACTIVE_NOT_RECRUITING", "page": 117 }, "page_size": 10 }, "pagination": { "page": 117, "page_size": 10, "total_count": 10532, "total_pages": 1054, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=118&status=ACTIVE_NOT_RECRUITING&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=116&status=ACTIVE_NOT_RECRUITING&page_size=10" }, "source": "local", "last_synced_at": "2026-11-04T21:55:01.724Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03778229", "title": "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Savolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2019-01-09", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-03T14:16:06.642Z", "location_count": 11, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03778229" }, { "nct_id": "NCT03698019", "title": "A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Mucosal Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2019-02-15", "completion_date": "2026-10-30", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-03T05:54:51.590Z", "location_count": 815, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03698019" }, { "nct_id": "NCT03625349", "title": "Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Aging", "Cardiovascular Disease" ], "interventions": [ { "name": "NG-Monomethyl-L-Arginine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2015-09-01", "completion_date": "2027-10-29", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-03T08:29:36.860Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03625349" }, { "nct_id": "NCT03059940", "title": "Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "Anti-Smoking Drug", "type": "DRUG" }, { "name": "Carbon Monoxide (CO) Level Test", "type": "OTHER" }, { "name": "Cessation Counseling", "type": "BEHAVIORAL" }, { "name": "Low Dose Computed Tomography Scan", "type": "PROCEDURE" }, { "name": "Nicotine Patch", "type": "DRUG" }, { "name": "Pharmacotherapy Discussion", "type": "BEHAVIORAL" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Quitline", "type": "BEHAVIORAL" }, { "name": "Shared Decision Making + Video", "type": "OTHER" }, { "name": "Tobacco Treatment Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 630, "start_date": "2017-06-16", "completion_date": "2027-01-15", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-03T00:29:19.733Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03059940" }, { "nct_id": "NCT03016871", "title": "Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2017-05-08", "completion_date": "2027-04-30", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-02T14:27:41.152Z", "location_count": 4, "location_summary": "Duarte, California • New Haven, Connecticut • Houston, Texas + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016871" }, { "nct_id": "NCT02827877", "title": "Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Positive Breast Carcinoma", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "Copper Cu 64-DOTA-Trastuzumab", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2018-02-14", "completion_date": "2027-08-26", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-03T05:32:44.458Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02827877" }, { "nct_id": "NCT02701283", "title": "Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aortic Valve Stenosis" ], "interventions": [ { "name": "Medtronic Transcatheter Aortic Valve Replacement Systems", "type": "DEVICE" }, { "name": "Surgical Aortic Valve Replacement (SAVR)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic Cardiovascular", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2223, "start_date": "2016-03", "completion_date": "2029-06", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-04T21:55:01.724Z", "location_count": 61, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02701283" }, { "nct_id": "NCT02659930", "title": "Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kaposi Sarcoma" ], "interventions": [ { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 62, "start_date": "2016-01-13", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-02T19:54:13.821Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02659930" }, { "nct_id": "NCT02595424", "title": "Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Neuroendocrine Carcinoma", "Intestinal Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2015-11-06", "completion_date": "2029-01-01", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-02T16:29:27.662Z", "location_count": 673, "location_summary": "Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595424" }, { "nct_id": "NCT02445391", "title": "Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Progesterone Receptor Negative", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2015-10-20", "completion_date": "2031-03-29", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-03T04:47:33.412Z", "location_count": 1023, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02445391" } ] }